Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer
Recruiting · NCT04300062 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Rebiopsy
What this trial is about
The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI. The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Diagnosed NSCLC or SCLC;
- Patient treated priorly by ICI and progressed under ICI;
- Have provided written informed consent for the study;
- Be \>/= 18 years of age on day of signing informed consent.
Exclusion criteria
- Patient under guardianship or curatorship;
- Unable to provide written informed consent for the study;
- Technical impossibility to carry out tissular rebiopsy under local anesthesia.
Where it is running
1 location listed.
- Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP - Boulogne-Billancourt, France